SCN2A and epilepsy: Although the precise upstream pathways driving CBD‐induced DEC2 expression require further elucidation, our findings suggest that enhancement of DEC2‐mediated SCN2A repression may represent an innovative therapeutic strategy for drug‐resistant epilepsy.